Lanean...
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
SUMMARY: Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate the cost-effectiveness of denosumab in a Swedish setting, also accounting for poor adherence to treatment. Denosumab is cost-effective, particularly for patients at high risk of fracture and lo...
Gorde:
| Argitaratua izan da: | Osteoporos Int |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5104532/ https://ncbi.nlm.nih.gov/pubmed/20936401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-010-1424-x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|